Rigel Pharmaceuticals highlights new data in three poster presentations at ASCO

Rigel Pharmaceuticals announced the presentation of three posters at the 2024 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago, IL today and online. Presentations include five-year results from the pivotal cohort of the registrational Phase 2 trial of REZLIDHIA for the treatment of relapsed or refractory mutated isocitrate dehydrogenase-1 acute myeloid leukemia, the safety and efficacy of olutasidenib treatment in a subgroup analyses of elderly patients with R/R mIDH1 AML, and an overview of the ongoing Phase 1b trial of R2891, a potent and selective inhibitor of IRAK1 and IRAK4, in patients with lower-risk myelodysplastic syndrome. “Our presentations at ASCO build on the strength of REZLIDHIA’s data, reinforcing its important role in the R/R mIDH1 AML treatment landscape. REZLIDHIA continues to demonstrate durable responses and was well tolerated, even in difficult to treat and elderly patients with mIDH1 AML who have more safety concerns,” said Raul Rodriguez, Rigel’s president and CEO. “In addition, we are sharing an overview of the ongoing Phase 1b trial of R289 in lower-risk MDS, an area of high unmet need. We believe R289 could potentially provide a new treatment option to patients who have failed other agents.”